// App-Quantinova.ai

: Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

Researchers

Presenter

  • Paul Knoebl

Principal Investigators

  • Wolfgang R. Sperr

  • Peter Schellongowski

  • Thomas Staudinger

  • Petra Jilma-Stohlawetz

  • Peter Quehenberger

  • Silvia Koder

  • Cihan Ay

  • Karoline V. Gleixner

Medical Centers

  • Dept. of Medicine I, Div. of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

  • Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

  • Dept. Med. 1, Intensive Care Unit, Medical University Vienna, Vienna, AUT

  • Dept.Med.1, Intensive Care Unir, Med. Univ. Vienna, Vienna, Austria

  • Department of Medicine I, Medical University of Vienna, Austria

  • Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria

  • Dept.Med.1, Div.Hematology and Hemostasis, Med.Univ.Vienna, Vienna, Austria

  • Medical University of Vienna, Vienna, Austria

  • Dept. of Medicine I, Div. of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

Locations

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Central Nervous System (CNS)

  • Gastroenterology (GU)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Hemophilia

  • Obesity

  • Hematoma

  • Stroke

  • Gastric antral vascular ectasia

Biomarkers

  • Activated partial thromboplastin time

Drug/Treatment

  • Prothrombin complex

  • FVIII

  • Hemostatic Solution

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved